Celldex Therapeutics (CLDX) Competitors $23.55 -2.19 (-8.51%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CLDX vs. VIVO, NTLA, HSKA, OXFD, HALO, IONS, ALKS, FOLD, GERN, and LGNDShould you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Heska (HSKA), Oxford Immunotec Global (OXFD), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Geron (GERN), and Ligand Pharmaceuticals (LGND). These companies are all part of the "medical" sector. Celldex Therapeutics vs. Meridian Bioscience Intellia Therapeutics Heska Oxford Immunotec Global Halozyme Therapeutics Ionis Pharmaceuticals Alkermes Amicus Therapeutics Geron Ligand Pharmaceuticals Meridian Bioscience (NASDAQ:VIVO) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking. Does the media refer more to VIVO or CLDX? In the previous week, Celldex Therapeutics had 19 more articles in the media than Meridian Bioscience. MarketBeat recorded 19 mentions for Celldex Therapeutics and 0 mentions for Meridian Bioscience. Celldex Therapeutics' average media sentiment score of 0.39 beat Meridian Bioscience's score of 0.00 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Meridian Bioscience Neutral Celldex Therapeutics Neutral Do analysts prefer VIVO or CLDX? Celldex Therapeutics has a consensus price target of $62.25, suggesting a potential upside of 164.33%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Meridian Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Meridian Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 Does the MarketBeat Community favor VIVO or CLDX? Celldex Therapeutics received 300 more outperform votes than Meridian Bioscience when rated by MarketBeat users. Likewise, 75.12% of users gave Celldex Therapeutics an outperform vote while only 48.77% of users gave Meridian Bioscience an outperform vote. CompanyUnderperformOutperformMeridian BioscienceOutperform Votes31648.77% Underperform Votes33251.23% Celldex TherapeuticsOutperform Votes61675.12% Underperform Votes20424.88% Which has better valuation & earnings, VIVO or CLDX? Meridian Bioscience has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Meridian Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMeridian Bioscience$333.02M4.49$42.46M$0.9735.02Celldex Therapeutics$9.98M156.62-$141.43M-$2.57-9.16 Which has more risk & volatility, VIVO or CLDX? Meridian Bioscience has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Do insiders & institutionals believe in VIVO or CLDX? 89.7% of Meridian Bioscience shares are owned by institutional investors. 2.3% of Meridian Bioscience shares are owned by company insiders. Comparatively, 3.8% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is VIVO or CLDX more profitable? Meridian Bioscience has a net margin of 12.70% compared to Celldex Therapeutics' net margin of -1,544.32%. Meridian Bioscience's return on equity of 16.74% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Meridian Bioscience12.70% 16.74% 13.09% Celldex Therapeutics -1,544.32%-19.75%-18.86% SummaryCelldex Therapeutics beats Meridian Bioscience on 11 of the 19 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDX vs. The Competition Export to ExcelMetricCelldex TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.56B$2.51B$5.07B$8.66BDividend YieldN/A0.74%5.10%4.06%P/E Ratio-9.165.93101.9117.46Price / Sales156.6227.501,195.1369.04Price / CashN/A15.1341.0436.36Price / Book1.993.036.345.87Net Income-$141.43M$29.98M$119.64M$225.66M7 Day Performance-10.18%-11.24%-5.13%-1.34%1 Month Performance-18.06%-12.49%-2.72%1.15%1 Year Performance-19.04%-20.97%31.10%24.02% Celldex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDXCelldex Therapeutics2.7984 of 5 stars$23.55-8.5%$62.25+164.3%-15.3%$1.56B$9.98M-9.16160Insider BuyingVIVOMeridian Bioscience1.0694 of 5 stars$33.97flatN/AN/A$1.50B$333.02M35.02702NTLAIntellia Therapeutics4.5291 of 5 stars$13.97-7.6%$55.36+296.3%-46.3%$1.42B$36.28M-2.57600Gap UpHigh Trading VolumeHSKAHeskaN/A$119.99flatN/AN/A$1.31B$257.31M-62.17808Analyst ForecastOXFDOxford Immunotec GlobalN/A$21.99flatN/AN/A$570.90M$73.71M-32.82273HALOHalozyme Therapeutics4.983 of 5 stars$45.65-15.4%$61.11+33.9%+15.5%$5.81B$829.25M15.12390News CoverageGap DownHigh Trading VolumeIONSIonis Pharmaceuticals4.0875 of 5 stars$34.34-7.8%$60.65+76.6%-29.3%$5.42B$803.07M-14.07800Analyst DowngradeInsider SellingShort Interest ↑News CoverageALKSAlkermes4.724 of 5 stars$28.19-0.6%$35.42+25.6%+20.6%$4.56B$1.51B14.462,100Analyst ForecastInsider SellingFOLDAmicus Therapeutics4.6688 of 5 stars$9.68-4.1%$17.63+82.1%-8.7%$2.89B$493.67M-28.47480Analyst ForecastShort Interest ↓GERNGeron3.5173 of 5 stars$3.66-1.3%$7.05+92.6%+95.7%$2.21B$29.48M-11.44141LGNDLigand Pharmaceuticals4.9911 of 5 stars$111.71-3.2%$144.83+29.7%+95.5%$2.11B$152.42M44.5180Analyst Forecast Related Companies and Tools Related Companies Meridian Bioscience Alternatives Intellia Therapeutics Alternatives Heska Alternatives Oxford Immunotec Global Alternatives Halozyme Therapeutics Alternatives Ionis Pharmaceuticals Alternatives Alkermes Alternatives Amicus Therapeutics Alternatives Geron Alternatives Ligand Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLDX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
